Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty

  • Peter A. Lee
  • , Karen Klein
  • , Nelly Mauras
  • , Kirk E. Neely
  • , Clifford A. Bloch
  • , Lois Larsen
  • , Cynthia Mattia-Goldberg
  • , Kristof Chwalisz
  • Pennsylvania State University
  • Indiana University-Purdue University Indianapolis
  • University of California at San Diego
  • Stanford University
  • Pediatric Endocrine Associates
  • University of Colorado Anschutz Medical Campus
  • Abbott Laboratories

Producción científica › revisión exhaustiva

76 Citas (Scopus)

Resumen

Context: GnRH agonist (GnRHa) monthly injections are frequently used in the treatment of central precocious puberty (CPP). The 3-month leuprolide depot 11.25- and 30-mg formulations are newly approved treatment options. Objective: The aim of the study was to investigate the safety and efficacy of leuprolide acetate 3-month depot formulations for the treatment of CPP in children. Design: This was a phase III, randomized, open-label, dose-ranging 6-month study. Setting: Twenty-two U.S. medical centers (including Puerto Rico) participated. Patients: Children diagnosed with CPP (n = 84), who were either treatment naive or previously treated with GnRHa, were recruited. Chronological age at onset of pubertal signs was less than 8 yr in girls and less than 9 yr in boys, and bone age was advanced over chronological age at least 1 yr. Intervention: Leuprolide acetate depot (11.25 or 30 mg) was administered im every 3 months. Main Outcome Measures: Biochemical [peak-stimulated LH, estradiol (girls), and testosterone (boys)] and anthropometric (growth rate, bone age acceleration, pubertal progression) parameters and safety were assessed. Results: Peak-stimulated LH was suppressed in the 11.25-and 30-mg dose groups in 78.4 and 95.2%, respectively, of children from months 2 through 6. There were nine treatment failures (peakstimulated LH >4 IU/liter) in the 11.25-mg group and two in the 30-mg group. Basal sex steroid suppression, growth rates, pubertal progression, bone age advancement, and adverse events were similar with either dose. Conclusions: Treatment with leuprolide acetate 3-month depot formulations (11.25 and 30 mg) effectively suppressed the GnRH axis, was well tolerated, and may positively impact patient convenience and compliance.

Idioma originalEnglish
Páginas (desde-hasta)1572-1580
Número de páginas9
PublicaciónJournal of Clinical Endocrinology and Metabolism
Volumen97
N.º5
DOI
EstadoPublished - may 2012

Huella

Profundice en los temas de investigación de 'Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty'. En conjunto forman una huella única.

Citar esto